Bernard A. Fox, Co-founder, President and CEO of UbiVac, shared a post by Vivenko on LinkedIn, adding:
”What is Cancer immunotherapy and how is it evolving???
FIRST: It is much much more that checkpoint blockers (Aka: anti-PD1, PDL1, CTLA4, & LAG3) that can work when a patient’s immune system is turned on.
Unfortunately, most patients with cancer have an immune system that doesn’t recognize their cancer, so Checkpoint Blockers Fail Those Patients.
This is where combination immunotherapy that includes cancer vaccines is already making a difference! The field is changing and moving at hyperspeed! Neoantigens, TAAs, and the recently described Dark Genome-derived Dark Matter antigens – the non-canonical Dark Proteome that have only recently been discovered and appear to be, in Pancreatic Cancer, Lung Cancer, NSCLC, and Melanoma , a majority of targets available for the immune system to recognize.
THE DISCUSSION ON THIS, AND MUCH MORE, WILL HAPPEN AT VAX ON 2025
VAX ON 2025 Will have the experts that are doing the research at the Cutting Edge and will cover all the topics and answer questions!
PDF of Program at link here.
BY THE WAY!!!! There will be more on this at SITC 2025”
Quoting Vivenko’s post:
”VAX ON. Vaccines: Present and Future in Oncology
WHERE: Bianca Maria Palace Hotel, Viale Bianca Maria 4, Milan, Italy
WHEN: October 1st, 2025
These are exciting times for cancer immunotherapy, as President Bernard A. Fox explains in this video, highlighting some of the topics that will be discussed at the meeting.
Watch the video and see you at VAX ON.
Presidency: Paolo A. Ascierto, Bernard A. Fox
Download the Scientific Program and Sign up:
Info: [email protected]”
Proceed to the video attached to the post.
More posts featuring Bernard A. Fox.